HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PHA 680626

has antineoplastic activity

Also Known As:

PHA-680626; PHA680626

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - PHA 680626: 2
    - Pyrazoles: 61
      - PHA 680626: 2

Experts

1.	Ascanelli, Camilla: 1 article (12/2021)
2.	Boi, Dalila: 1 article (12/2021)
3.	Capelli, Davide: 1 article (12/2021)
4.	Carpinelli, Patrizia: 1 article (12/2021)
5.	Contestabile, Roberto: 1 article (12/2021)
6.	Costi, Roberta: 1 article (12/2021)
7.	De Leo, Alessandro: 1 article (12/2021)
8.	Di Santo, Roberto: 1 article (12/2021)
9.	Guarguaglini, Giulia: 1 article (12/2021)
10.	Lindon, Catherine: 1 article (12/2021)

Related Diseases

1.	Leukemia 12/01/2008 - "Thus, both Bcr-Abl and Aurora kinase inhibition contribute to the efficacy of PHA-680626 against Imatinib-resistant BCR-ABL positive leukemias, particularly those harbouring the T315I mutation."
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/01/2008 - "PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases."
3.	Neuroblastoma 12/04/2021 - "Our results identify PHA-680626 as an amphosteric inhibitor both in vitro and in MYCN overexpressing cell lines, thus expanding the repertoire of known conformational disrupting inhibitors of the AURKA/N-Myc complex and confirming that altering the conformation of the activation loop of AURKA with a small molecule is an effective strategy to destabilize the AURKA/N-Myc interaction in neuroblastoma cancer cells."
4.	Neoplasms (Cancer) 12/04/2021 - "Our results identify PHA-680626 as an amphosteric inhibitor both in vitro and in MYCN overexpressing cell lines, thus expanding the repertoire of known conformational disrupting inhibitors of the AURKA/N-Myc complex and confirming that altering the conformation of the activation loop of AURKA with a small molecule is an effective strategy to destabilize the AURKA/N-Myc interaction in neuroblastoma cancer cells."
5.	Blast Crisis (Blast Phase) 12/01/2008 - "Moreover, high anti-proliferative activity of PHA-680626 was observed in primary CD34+ cells derived from CML patients at diagnosis or in blast crisis as well as from an individual harbouring the T315I mutation. "

Related Drugs and Biologics

1.	Aurora Kinases
2.	Imatinib Mesylate (Gleevec)
3.	Aurora Kinase A
4.	bcr-abl Fusion Proteins